Form 8-K - Current report:
SEC Accession No. 0001193125-25-176051
Filing Date
2025-08-08
Accepted
2025-08-08 07:37:31
Documents
14
Period of Report
2025-08-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d40493d8k.htm   iXBRL 8-K 25892
2 EX-99.1 d40493dex991.htm EX-99.1 55119
6 GRAPHIC g40493dsp1q.jpg GRAPHIC 3800
  Complete submission text file 0001193125-25-176051.txt   208922

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA akro-20250808.xsd EX-101.SCH 2849
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE akro-20250808_lab.xml EX-101.LAB 17993
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akro-20250808_pre.xml EX-101.PRE 11260
16 EXTRACTED XBRL INSTANCE DOCUMENT d40493d8k_htm.xml XML 3653
Mailing Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 650-487-6488
Akero Therapeutics, Inc. (Filer) CIK: 0001744659 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38944 | Film No.: 251196213
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)